What is the TIMI Score for UA/NSTEMI?
The TIMI risk score for UA/NSTEMI is a simple 7-point scoring system developed from the TIMI 11B trial. It predicts the risk of a composite endpoint of all-cause mortality, new or recurrent myocardial infarction, and severe recurrent ischemia requiring urgent revascularization within 14 days of presentation.
Each of the 7 criteria is worth 1 point, and the total score ranges from 0 to 7. The score was validated in the ESSENCE trial and has become one of the most widely used risk stratification tools in emergency medicine and cardiology for managing patients with non-ST-elevation acute coronary syndromes.
Scoring Criteria
| Criterion | Points | Rationale |
|---|---|---|
| Age ≥ 65 years | 1 | Age is an independent predictor of adverse outcomes in ACS |
| ≥ 3 CAD risk factors | 1 | Multiple risk factors indicate higher baseline atherosclerotic burden |
| Known CAD (stenosis ≥ 50%) | 1 | Established coronary disease worsens prognosis |
| Aspirin use in past 7 days | 1 | Implies aspirin-resistant disease or breakthrough events on therapy |
| Severe angina (≥ 2 episodes in 24h) | 1 | Indicates high-grade, active ischemia |
| ST changes ≥ 0.5 mm | 1 | ECG evidence of active ischemia increases risk |
| Positive cardiac marker | 1 | Troponin elevation indicates myocardial necrosis (NSTEMI vs UA) |
Score Interpretation
| TIMI Score | 14-Day Event Rate | Risk Level | Recommendation |
|---|---|---|---|
| 0–1 | 4.7% | Low | Conservative management may be appropriate |
| 2 | 8.3% | Low-Intermediate | Consider early invasive strategy |
| 3 | 13.2% | Intermediate | Early invasive strategy recommended |
| 4 | 19.9% | Intermediate-High | Early invasive strategy with GP IIb/IIIa inhibitor |
| 5 | 26.2% | High | Urgent invasive strategy |
| 6–7 | 40.9% | Very High | Urgent invasive strategy; ICU admission |
The composite endpoint includes: all-cause mortality, new or recurrent myocardial infarction, and severe recurrent ischemia requiring urgent revascularization—all within 14 days of presentation.
UA/NSTEMI Risk Diagram
UA/NSTEMI Overview
Unstable Angina (UA) and Non–ST-Elevation Myocardial Infarction (NSTEMI) are forms of acute coronary syndrome (ACS) that share similar pathophysiology but differ in the presence of myocardial necrosis. Both are caused by partial or intermittent coronary artery occlusion, typically due to plaque rupture or erosion with superimposed thrombosis.
- Unstable Angina: Ischemic symptoms at rest or with minimal exertion, with no elevation of cardiac biomarkers. ECG may show ST depression or T-wave inversions.
- NSTEMI: Same presentation as UA but with elevated cardiac troponin levels, confirming myocardial necrosis has occurred. ECG typically does not show persistent ST elevation.
Both conditions require urgent evaluation and risk stratification to determine the timing and type of invasive strategy (cardiac catheterization with possible revascularization).
Clinical Decision-Making
The TIMI score directly informs the management strategy for UA/NSTEMI patients:
- Low risk (0–2): Conservative strategy may be appropriate. Medical management with antiplatelet agents, anticoagulants, statins, and beta-blockers. Non-invasive stress testing before discharge to evaluate for inducible ischemia.
- Intermediate risk (3–4): Early invasive strategy (within 24 hours) is recommended. The TACTICS-TIMI 18 trial demonstrated that patients with TIMI scores ≥ 3 derive significant benefit from an early invasive approach.
- High risk (5–7): Urgent invasive strategy is warranted. These patients should undergo cardiac catheterization as soon as possible (ideally within 2–24 hours). Intensive antiplatelet and antithrombotic therapy should be initiated.
with an early invasive strategy compared to conservative management.
Comparison with Other Scores
| Feature | TIMI UA/NSTEMI | GRACE Score | HEART Score |
|---|---|---|---|
| Variables | 7 clinical | 8 (includes labs) | 5 clinical + labs |
| Endpoint | 14-day composite | In-hospital & 6-month mortality | 6-week MACE |
| Requires labs | Yes (troponin) | Yes (creatinine) | Yes (troponin) |
| Ease of use | Very simple | Moderate (needs calculator) | Simple |
| Best for | Quick bedside triage | Prognostication | Chest pain evaluation |
Frequently Asked Questions
What is the difference between UA and NSTEMI?
The key difference is troponin elevation. NSTEMI has elevated cardiac troponin levels indicating myocardial necrosis (cell death), while UA has normal troponin levels despite ischemic symptoms. Both present similarly with chest pain, ST depression, or T-wave inversions, but NSTEMI carries a higher short-term risk.
What counts as "known CAD" for this score?
Known CAD means documented coronary artery stenosis of 50% or greater on prior cardiac catheterization. Prior PCI, CABG, or a positive functional study (stress test with confirmed ischemia) may also qualify depending on clinical context.
Why is aspirin use a risk factor?
If a patient is already on aspirin and still presents with an acute coronary event, this suggests either aspirin-resistant disease or a high-risk thrombotic process that overcomes the antiplatelet effect. These patients may have more aggressive underlying disease.
Should treatment be delayed for score calculation?
No. The TIMI score should be calculated concurrently with initiating standard ACS treatment (aspirin, anticoagulation, monitoring, serial ECGs, troponin). It helps guide the timing of invasive strategy but should never delay initial stabilization.
Is the TIMI score used for STEMI patients?
No. STEMI patients have a separate TIMI score with different variables and point values. The UA/NSTEMI score should only be applied to patients without persistent ST-segment elevation who present with symptoms suggestive of ACS.